Curated news and analysis on clinical trials, drug approvals, and medical research.
Louisiana regulators voted to fast-track Entergy’s $21 billion proposal tied to Meta’s planned Richland Parish data center. Analyses cited in the debate say the policy could shift more than half of related power costs to ratepayers and add $14 billion to $26 billion in wholesale electricity system costs over 15 years.
The University of Cincinnati Cancer Center’s Blood Cancer Healing Center added research laboratories and the UC Osher Wellness Suite and Learning Kitchen. The expansion joins clinical services launched in July 2024 and adds new research, wellness and community programming space.
A perspective article says global regulatory frameworks for generative AI medical devices are an urgent priority. It highlights risks, limits of current rules, and the need for multidisciplinary collaboration.
Studies in muscle-invasive bladder cancer found ctDNA predicted metastatic risk after bladder-sparing treatment, while urine tumor DNA was more sensitive for residual bladder disease. Data from RETAIN-2 and a PNAS study support molecular testing to help select patients for bladder preservation.
PDS Biotechnology announced positive interim Phase 2 Stage 1 data for PDS01ADC plus HAIP in MSS/pMMR colorectal liver metastases. The trial showed a 77.8% objective response rate and about 85% 24-month survival in 9 patients.
Heather Quintana Suchan said early biomarker testing and genomic profiling identified an exon 20 mutation and helped match her to Rybrevant for stage 4 lung cancer. She said the treatment is working well with minimal side effects and is urging patients to seek personalized testing early.
Researchers developed an AI-driven drug discovery platform that models protein flexibility during molecular binding. The suite includes YuelDesign, YuelPocket and YuelBond.
Scientists at NTU Singapore developed an AI-powered biochip that detects multiple microRNA biomarkers in 20 minutes. The platform achieved more than 99 per cent accuracy in test channels.
The FDA has expanded animal drug options for New World screwworm through conditional approvals and emergency use authorizations. The agency lists products for cattle, dogs and cats and says its guidance page will be updated as more drugs move through the system.
A study found seniors with screening-detected atrial fibrillation had a roughly threefold higher risk of heart failure. Heart failure was often diagnosed within six months.
Registered nurses at Baystate Franklin Medical Center voted 98.2% to authorize a potential 1-3 day strike after filing an unfair labor practice charge over a staffing proposal. The dispute centers on use of a non-union float pool, nurse-patient limits, wages, and recruitment and retention.
The global healthcare contract research organization market is estimated at USD 60.66 billion in 2025 and is expected to reach USD 124.56 billion by 2035. North America led in 2025, while Asia Pacific is projected to post the fastest growth.
Artificial intelligence is being adopted across clinical development and could shorten drug development timelines by roughly 18 months while lowering R&D spending by about 5%. Data provenance and consent frameworks remain key issues as pharma companies expand AI use.
Johnson & Johnson raised its full-year forecast after stronger-than-expected quarterly results driven by cancer, immunology and neuroscience drugs. Sales were $24.56 billion and adjusted earnings were $2.46 per share, with Innovative Medicines sales rising 10.0% to $15.76 billion.
A study published in The Journal of Clinical Investigation found that CXCL11 may help drive endocrine resistance in some hormone receptor-positive breast cancers. Researchers said ED-resistant tumors had increased immune signaling and may be more responsive to immunotherapies.
PJM has proposed a two-phase Reliability Backstop Procurement and a framework for large new loads to bring their own generation or scale back usage. The plan could speed bilateral power deals for data centers while adding a backstop auction to address supply shortfalls.
Lenacapavir was launched in Zimbabwe in February 2026 as Kenya became the fourth African country to start administering the twice-yearly HIV prevention injection. The rollout follows launches in Eswatini and Zambia in December 2025, five months after US FDA approval.
Samsung Bioepis plans to start a global Phase 1 trial of SBE303, its first independently developed new drug candidate targeting Nectin-4. Preclinical data showed tolerability up to 40 mg/kg in monkeys.
Virginia lawmakers are again advancing a Prescription Drug Affordability Board bill, while Gov. Abigail Spanberger seeks amendments. The measure would create a board to analyze drug pricing and apply federal caps to state-regulated plans.
Breath Diagnostics said the FDA granted Breakthrough Device Designation to its OneBreath platform for pre-operative assessment of postoperative pneumonia risk in adults undergoing elective cardiac surgery. The single-breath test analyzes exhaled volatile organic compounds using LC-MS and is intended for use with clinical evaluation and standard risk assessment tools.
